Brachytherapy

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Wednesday, July 19, 2023
Women, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Oncology, MSD, Bevacizumab, Obstetrics, Progression-free survival, Catholic higher education, OS, MRK, Research, PFS, Merck & Co., HIV disease progression rates, Cervical cancer, Patient, CPS, Brachytherapy, EBRT, Gynaecology, GOG, Data monitoring committee, Chemoradiotherapy, Recurrence, PD-L1, NYSE, Disease, Pharmaceutical industry, Merck

A favorable trend in overall survival (OS), the trial’s other primary endpoint, was also observed for KEYTRUDA plus concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone; however, these OS data were not mature at the time of this interim analysis.

Key Points: 
  • A favorable trend in overall survival (OS), the trial’s other primary endpoint, was also observed for KEYTRUDA plus concurrent chemoradiotherapy compared to concurrent chemoradiotherapy alone; however, these OS data were not mature at the time of this interim analysis.
  • The trial is continuing and follow-up of OS is ongoing.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • “We are encouraged by these results that show treatment with KEYTRUDA significantly improved progression-free survival for patients with newly diagnosed high-risk locally advanced cervical cancer.

CIVCO Radiotherapy and Qfix Showcase as One Company at AAPM 2023

Retrieved on: 
Monday, July 17, 2023
Transfer, SBRT, American Association of Physicists in Medicine, Body, SRS, Anatomy, AAPM, Head, Brain, CNS, Radiation therapy, Physicist, MRI, Patient, Symphony, Annual general meeting, Encompass, Brachytherapy, Fluoroscopy, Tesla, Penile implant, Integration, Fiducial marker, Telescopic sight, Medical imaging, Medicine

CORALVILLE, Iowa, July 17, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix, now together as one company, will exhibit their innovative and patented solutions during the annual American Association of Physicists in Medicine (AAPM) 65th Annual Meeting in Houston, Texas, July 23-27, 2023.

Key Points: 
  • CORALVILLE, Iowa, July 17, 2023 /PRNewswire/ -- CIVCO Radiotherapy and Qfix, now together as one company, will exhibit their innovative and patented solutions during the annual American Association of Physicists in Medicine (AAPM) 65th Annual Meeting in Houston, Texas, July 23-27, 2023.
  • The company encourages attendees to visit booth #1411 to experience many of these solutions firsthand.
  • SBRT bridges, belts, and additional customization options are also available with the Alta™ Multipurpose Device (including Patient Transfer).
  • The Encompass™ and Solstice™ SRS Immobilization Systems are highly advanced, non-invasive solutions designed for precisely targeted brain, head, and neck treatments.

Tampa General Hospital Named One of America's Top Cancer Hospitals by Newsweek

Retrieved on: 
Wednesday, June 28, 2023
Proton, Online, News, Cyberknife, Medicine, Partnership, Accreditation, Cancer Institute, Education, COC, Proton therapy, Multiple myeloma, Hospital, Commission, Radiation, Quality of life, Research, HDR, BMT, University of Florida Cancer and Genetics Research Complex, Radiopharmaceutical, Radiation therapy, Patient, Tampa General Hospital, Reno CyberKnife, U.S. News & World Report, ACS, Lymphoma, TGH, Cell, Brachytherapy, Statista, Health, American College, Dentistry, Nursing, Pharmaceutical industry, Oncology, Newsweek, Tampa Bay, Cancer

TAMPA, Fla., June 28, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) is in the top 3% of cancer hospitals in the United States, according to Newsweek and Statista. Listed in the news magazine's new America's Best Cancer Hospitals 2023 rankings, Tampa General is also ranked in the top 10 Florida cancer facilities that appear on Newsweek's list.

Key Points: 
  • Tampa General Hospital Cancer Institute is ranked among the best cancer hospitals nationally.
  • TAMPA, Fla., June 28, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) is in the top 3% of cancer hospitals in the United States, according to Newsweek and Statista.
  • Listed in the news magazine's new America's Best Cancer Hospitals 2023 rankings, Tampa General is also ranked in the top 10 Florida cancer facilities that appear on Newsweek's list.
  • "This recognition is a testament to the incredible oncology team that leads the TGH Cancer Institute to deliver world-class, cutting-edge and compassionate cancer care," said John Couris, president and CEO of Tampa General.

Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference

Retrieved on: 
Tuesday, June 27, 2023
Prostate brachytherapy, UPMC Hillman Cancer Center, Head, Brain, Radiation therapy, Neck, Rated R, Lung, Hereditary nonpolyposis colorectal cancer, ABS, CATX, Patient, UPMC, Therapy, NYSE, Prostate cancer, Medical imaging, Brachytherapy, IOWA, MD

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.

Key Points: 
  • RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.
  • The authors reported that Cesium-131 prostate brachytherapy provided disease-free survival rates of 97.8% and 96%, at 5 and 10 years respectively.
  • “We’re excited that a presentation of long-term clinical data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ABS meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer.
  • He added, “The data shows Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% ten years after treatment.

Radiation therapy treatment rates show improved efficiency, finds New IMV Market Summary Report

Retrieved on: 
Thursday, June 22, 2023
Brainlab, IMV, Accuray, RaySearch Laboratories, Radiation, Cerner, Hospital, Patient, IBA, Com, Brachytherapy, EBRT, Growth, OEM, Medical imaging, Nursing, Science, Elekta, Varian

But these particular data points in the report -- called the IMV 2022-2023 Radiation Therapy Market Summary – reflect a gain in the efficiency of treating patients with radiation therapy, in part due as well to a 5.4% decrease in the average number of visits per course of treatment, report lead and IMV senior market research program manager Davin Korstjens said.

Key Points: 
  • Reduced Number of Patient Visits Needed per Course of Radiation Therapy Treatment, according to a recent IMV's 2022-2023 Radiation Therapy Market Summary report.
  • But these particular data points in the report -- called the IMV 2022-2023 Radiation Therapy Market Summary – reflect a gain in the efficiency of treating patients with radiation therapy, in part due as well to a 5.4% decrease in the average number of visits per course of treatment, report lead and IMV senior market research program manager Davin Korstjens said.
  • The report also found that, although the external beam radiation therapy installed base in the U.S. decreased by 3.3% in 2022, 50% of radiation therapy sites are considering the purchase of an EBRT system in the next three years, Korstjens said.
  • IMV's 2022-2023 Radiation Therapy Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, and site operations characteristics.

Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting

Retrieved on: 
Friday, June 16, 2023
SBRT, University, Radiopharmaceutical, University of Pittsburgh Medical Center, Head, Brain, UPMC Hillman Cancer Center, Radiation therapy, Neck, Lung, Radiosurgery, Hereditary nonpolyposis colorectal cancer, ABS, CATX, MD, Patient, Risk, Annual general meeting, Cancer, UPMC, Therapy, NYSE, Prostate cancer, Medical imaging, Brachytherapy, IOWA

“We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.

Key Points: 
  • “We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.
  • He added, “We’re also excited to note that the American Brachytherapy Society is including a session entitled, ‘Implementation of Radiopharmaceuticals in the Radiation Oncology Clinic’.
  • Dr. Smith has extensive experience with Cesium-131 brachytherapy for prostate cancer and has treated over 1,000 patients at UPMC.
  • Andrew Bright, Perspective Therapeutics’ EVP of Brachytherapy, added, “Long-term outcomes have already demonstrated the significance of Cesium-131 brachytherapy for prostate cancer treatment.

Perspective Therapeutics Reports First Quarter Fiscal 2023 Results

Retrieved on: 
Tuesday, May 16, 2023
Viewpoint, Glomus tumor, Cancer, Research, Acquisition, CATX, Patient, Investment, Brachytherapy, R, Therapy, NYSE, Safety, Pharmaceutical industry, IOWA

RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports first quarter financial results for the period ended March 31, 2023.

Key Points: 
  • RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports first quarter financial results for the period ended March 31, 2023.
  • “Perspective Therapeutics is at an exciting juncture of our journey as we advance our clinical alpha-particle radiopharmaceutical pipeline.
  • Simultaneously, we look to further support revenue expansion of our commercial brachytherapy program,” said Thijs Spoor, Perspective Therapeutics’ CEO.
  • “In 2023, we expect to report provisional results from ongoing compassionate use of VMT-α-NET for neuroendocrine tumors.

RaySearch expands collaboration with BEBIG Medical

Retrieved on: 
Monday, May 15, 2023
Brachytherapy, RaySearch Laboratories, Partnership, Patient, Pharmaceutical industry, Medical imaging

RaySearch and BEBIG have collaborated to integrate RaySearch's advanced treatment planning system RayStation®* and oncology information system RayCare®* with BEBIG Medical's brachytherapy system.

Key Points: 
  • RaySearch and BEBIG have collaborated to integrate RaySearch's advanced treatment planning system RayStation®* and oncology information system RayCare®* with BEBIG Medical's brachytherapy system.
  • In addition, RaySearch's software solutions will be further integrated with the Shinva Linac, which BEBIG Medical is distributing globally.
  • Mr. George Chan, Chairman and CEO of BEBIG Medical, says: "Our existing strong partnership with RaySearch has paved a solid way to integrate our brachytherapy solutions into modern radiation workflows.
  • Johan Löf, Founder and CEO, RaySearch, says: "We look forward to deepening our strategic partnership with BEBIG Medical.

Perspective Therapeutics Expands Management Team And Names Andrew Bright as Executive Vice-President of Brachytherapy

Retrieved on: 
Monday, April 3, 2023
Seed, WA, Catalog, Brain, Prostate, Lung, CATX, Patient, Physician, Cancer, Growth, Therapy, NYSE, Prostate cancer, Medical imaging, Brachytherapy

RICHLAND, WA & CORALVILLE, IA, April 03, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, expands management team and names Andrew Bright as Executive Vice-President of Brachytherapy. The appointment advances Perspective Therapeutics’ aspirations as a global leader in the manufacturing and distribution of Cesium-131 brachytherapy radioisotope seeds. Brachytherapy seeds have been designed to treat a variety of cancers including prostate, head & neck, lung and brain.

Key Points: 
  • RICHLAND, WA & CORALVILLE, IA, April 03, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, expands management team and names Andrew Bright as Executive Vice-President of Brachytherapy.
  • The appointment advances Perspective Therapeutics’ aspirations as a global leader in the manufacturing and distribution of Cesium-131 brachytherapy radioisotope seeds.
  • Brachytherapy seeds have been designed to treat a variety of cancers including prostate, head & neck, lung and brain.
  • Thijs Spoor, Perspective Therapeutics’ CEO commented on the appointment: “We are delighted to have a senior leader of Andrew Bright’s caliber helm Perspective Therapeutics’ commercial brachytherapy business.

Radiance Therapeutics to present at LSI USA '23 Emerging Medtech Summit

Retrieved on: 
Thursday, March 16, 2023
Research, Technology, Medical Devices, Nanotechnology, Biotechnology, Radiology, General Health, Health, Optical, Science, Brachytherapy, Therapy, Glaucoma, MD, LSI, Partnership, Patient, Master of Science, FDA, Neoplasm, Medtech, Pharmaceutical industry, Radiance

MD, will be representing the company at the LSI USA '23 Emerging Medtech Summit, which will take place on March 20-23, 2023 in Dana Point, California.

Key Points: 
  • MD, will be representing the company at the LSI USA '23 Emerging Medtech Summit, which will take place on March 20-23, 2023 in Dana Point, California.
  • LSI USA ‘23 is a unique conference that brings together the most innovative emerging medtech players, accredited investors, and strategics looking for partnership and investment opportunities.
  • Hosted by Life Science Intelligence (LSI), a premium market intelligence company focused on the medtech industry, the LSI USA '23 Emerging Medtech Summit is a must-attend event for investors and innovators seeking opportunities for fruitful collaborations to forecast the future of medtech.
  • Radiance Therapeutics is developing a device for the treatment of glaucoma patients with the goal of reducing filtration surgery postoperative complications.